Press ReleasesMateria Malta Completes First Commercial Export Of Medical Cannabis...

Materia Malta Completes First Commercial Export Of Medical Cannabis To Germany

-

Materia (the “Company”), a leading producer and distributor of medical cannabis in Europe, announces that its wholly-owned subsidiary Materia Malta Operating Ltd. (“Materia Malta“) has completed its first export of commercial medical cannabis from its EU GMP manufacturing site.

This represents the launch of Materia’s own brand and manufactured products into Germany, Europe’s largest medical cannabis market. The Company’s German distribution subsidiary, Materia Deutschland GmbH, which took delivery of the shipment, has commenced sales to pharmacies, with a number of pre-orders already received.

Materia becomes the first Malta-based manufacturer of medical cannabis to export product for commercial sale in another country. Previous exports have only been approved for R&D or lab testing purposes.

“Our products are already helping patients in Malta improve their quality of life, and now we can support the needs of patients in Germany too,” said Nick Pateras, Managing Director, Europe of Materia.

“We believe Malta will play an important role in the global cannabis supply chain, as it has done within the broader pharmaceuticals sector for decades. We are proud to be the company establishing new frontiers for Malta’s and Europe’s cannabis industry.”

Update on Kanabo Transaction

The Company also informs that further to the announcements made on 26 July, 2021 and 4 November, 2021 regarding its proposed transaction with Kanabo Group Plc (“Kanabo”), discussions have developed such that both parties believe the relationship is best consummated through a contract manufacturing agreement, as opposed to the previously proposed transaction.  

The Company is seeking new strategic partners while it continues its organic growth and execution of its business plan. Discussions with potential partners are oriented around accelerating the Company’s penetration of key end markets and further bolstering its supply chain.

Latest news

Germany Seeing Sense, High Tide Strikes Deal With Major German Player, European Expansion For Bedrocan, Danish Buy-Out, Greek First, £2m UK Hemp Boost

THE German Government’s refreshingly honest approach to drugs and addiction is being demonstrated with a focus on the harms...

European Cannabis Stocks Review: Akanda Announces ‘First Significant Revenue Above Initial Projections’, Jazz Pharma Reimbursement Recommendation & Kanabo Climbs

Akanda  Akanda has enjoyed a sharp recovery in its share price this week, seeing its value return to levels not...

15% Of European Consumers Have Tried CBD, But Industry Held Back By ‘High Turnover Rate’ Of Users

THE European CBD market is set to see a ‘massive influx’ of previous and new consumers to the market...

Malta’s Pioneering Legal Cannabis Club Framework Announced, But Concerns Raised Licence Fees Could Push Many To Black Market

ON Friday (January 27) the Maltese Authority for the Responsible Use of Cannabis (ARUC) announced new guidelines set to...

Cannovum AG Establishes Cultivation Alliance For Germany

PRESS RELEASE CANNOVUM AG is currently founding the premier cultivation alliance for recreational cannabis in Germany. The aim of the...

Jazz Pharmaceuticals Receives NICE Recommendation For The Reimbursement Of Epidyolex (Cannabidiol) For The Treatment Of Seizures Associated With Tuberous Sclerosis Complex In England

PRESS RELEASE JAZZ Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Epidyolex® (cannabidiol,100 mg/mL oral solution), developed by GW Pharmaceuticals ("GW"; now...

Must read

You might also likeRELATED
Recommended to you